Edwards Lifesciences (NYSE:EW) Stock Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Edwards Lifesciences Corporation (NYSE:EW). In a filing disclosed on December 29th, the Representative disclosed that they had sold between $1,001 and $15,000 in Edwards Lifesciences stock on November 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dassault Systemes (OTCMKTS:DASTY) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of HubSpot (NYSE:HUBS) on 11/19/2025.
• Sold $15,001 – $50,000 in shares of Fidelity National Information Services (NYSE:FIS) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of KKR & Co. Inc. (NYSE:KKR) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 11/19/2025.
• Purchased $1,001 – $15,000 in shares of CSW Industrials (NYSE:CSW) on 11/17/2025.
• Sold $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 10/20/2025.
• Purchased $1,001 – $15,000 in shares of NiCE (NASDAQ:NICE) on 10/17/2025.
• Purchased $1,001 – $15,000 in shares of NetEase (NASDAQ:NTES) on 10/17/2025.

Edwards Lifesciences Stock Performance

NYSE EW opened at $86.17 on Wednesday. The company has a market cap of $50.01 billion, a P/E ratio of 37.14, a P/E/G ratio of 3.91 and a beta of 0.97. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The stock has a 50-day moving average of $84.28 and a two-hundred day moving average of $79.79.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on EW shares. Wells Fargo & Company set a $100.00 price objective on Edwards Lifesciences in a research note on Thursday, December 18th. National Bankshares set a $92.00 price target on Edwards Lifesciences in a report on Friday, October 31st. The Goldman Sachs Group set a $104.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday, October 31st. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research report on Monday, November 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $93.95.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $84.03, for a total value of $85,626.57. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,848,828.06. The trade was a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,465 shares of company stock valued at $3,804,610 in the last three months. 0.34% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $266,000. Quantbot Technologies LP purchased a new stake in Edwards Lifesciences in the first quarter valued at $26,000. Trexquant Investment LP acquired a new position in Edwards Lifesciences in the first quarter valued at $2,472,000. State of Wyoming boosted its stake in Edwards Lifesciences by 38.3% in the first quarter. State of Wyoming now owns 2,676 shares of the medical research company’s stock valued at $194,000 after acquiring an additional 741 shares in the last quarter. Finally, MAI Capital Management grew its holdings in shares of Edwards Lifesciences by 32.7% during the first quarter. MAI Capital Management now owns 85,927 shares of the medical research company’s stock worth $6,228,000 after purchasing an additional 21,192 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.